Halozyme Therapeutics (NASDAQ:HALO) Lifted to Buy at StockNews.com : vimarsana.com

StockNews.com upgraded shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) from a hold rating to a buy rating in a research report released on Monday morning. Other analysts also recently issued reports about the company. Benchmark reissued a buy rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a report on […]

Related Keywords

United States , Ireland , Belgium , Switzerland , Japan , Michaelj Labarre , , Halozyme Therapeutics Inc , Norges Bank , Thrivent Financial For Lutherans , Halozyme Therapeutics Company Profile , Arrowmark Colorado Holdings , Macquarie Group Ltd , Marshall Wace , Halozyme Therapeutics , Free Report , Moderate Buy , Get Free Report , Mark Colorado Holdings , Macquarie Group , Halozyme Therapeutics Daily , Nasdaq Halo , Halo , Medical , 40637h10 , Upgrade , Stocknews Com ,